Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $197.7 million.

  • Adma Biologics' Net Income towards Common Stockholders rose 1.45% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.1 million, marking a year-over-year increase of 275.18%. This contributed to the annual value of $197.7 million for FY2024, which is 800.00% up from last year.
  • Latest data reveals that Adma Biologics reported Net Income towards Common Stockholders of $197.7 million as of FY2024, which was up 800.00% from -$28.2 million recorded in FY2023.
  • Adma Biologics' 5-year Net Income towards Common Stockholders high stood at $197.7 million for FY2024, and its period low was -$76.6 million during FY2020.
  • Over the past 3 years, Adma Biologics' median Net Income towards Common Stockholders value was -$28.2 million (recorded in 2023), while the average stood at $34.5 million.
  • Data for Adma Biologics' Net Income towards Common Stockholders shows a peak YoY soared of 800.00% (in 2024) over the last 5 years.
  • Adma Biologics' Net Income towards Common Stockholders (Yearly) stood at -$76.6 million in 2020, then increased by 6.81% to -$71.4 million in 2021, then grew by 7.69% to -$65.9 million in 2022, then soared by 57.15% to -$28.2 million in 2023, then surged by 800.00% to $197.7 million in 2024.